Dr. Gill reviews the advantages and challenges of using the newly approved recombinant von WIllebrand factor replacement product in clinical practice.
Joan C. Gill, MD: New Recombinant Factors for von Willebrand Disease
Recent Articles
U.K. Labour Party Plans to Regulate Pharmaceutical Market, Lower Drug Prices
The U.K. Labour Party has pledged to reform the country’s pharmaceutical market by establishing a publicly owned generic drug manufacturer and expanding the government’s...
Federal Watchdog Report Shows NIH Must Better Protect U.S. Research From Foreign Influence
New reports issued by the U.S. Department of Health and Human Services (HHS) inspector general show that foreign governments and corporations could profit from...
23andMe Is Building a Clinical Trial Recruitment Business
Genetic testing kit company 23andMe announced that it will partner with startup TrialSpark to help match interested customers with nearby clinical trial sites based...
U.S. Political Tensions Rise as Pelosi and Grassley Release Drug Pricing Bills
While lowering drug costs is a major bipartisan voter issue, tensions between parties have been escalating as Democrats introduced a bill that would allow...
FDA Issues Guidelines for Regulating Health AI
The U.S. Food and Drug Administration (FDA) has issued new guidelines for mobile health software and clinical decision support (CDS) tools that use artificial...
Current Issue
October 2019, Volume 5, Issue 12
This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.
